The Priority Review

Category

Clinical trials

Trial starts, readouts, holds and designs.

267 stories · page 10 of 23

Stories

  1. On crovalimab, 59.5 percent of treatment-naive aHUS participants had a complete TMA response

    In the Phase III COMMUTE-a study, 59.5 percent of 37 treatment-naive participants with aHUS had a complete thrombotic microangiopathy response through Week 25, the registry shows. The record covers 83 participants in three cohorts.

  2. Boehringer Ingelheim registers Phase III trial of verducatib in COPD

    The AIRWARD Study plans to enroll 1800 participants with COPD and plans to start on March 10, 2027. It evaluates whether verducatib reduces flare-ups and improves lung function compared with placebo over up to 1.5 years.

  3. Hoffmann-La Roche posts results of Phase III crovalimab study in aHUS

    Results for the Phase III, single-arm study of crovalimab in adult and adolescent patients with atypical hemolytic uremic syndrome were first posted on ClinicalTrials.gov on October 30, 2026, after enrolling 83 participants. The study, which began on October 22, 2021, reached primary completion on October 9, 2025.

  4. PROSpect trial finds no difference in ventilator-free days with prone positioning or HFOV

    The PROSpect phase 3 trial, enrolling 424 of 600 planned patients, found no significant difference in ventilator-free days between prone and supine positioning (median 17·9 vs 17·4 days) or between HFOV and conventional ventilation (17·3 vs 18·0 days). The authors reported more frequent airway obstruction and immobility-related pressure injuries with prone positioning and more haemodynamic instability with HFOV, concluding that routine use of these strategies is not recommended.

  5. Abbott initiates CROWN-MV pivotal trial for Cephea device

    Abbott has started the CROWN-MV study, a prospective pivotal trial that will enroll up to 585 patients with symptomatic mitral valve disease in the U.S., Canada and Europe. The trial will evaluate the safety and effectiveness of the investigational Cephea Mitral Valve System, a catheter-based replacement option for patients not candidates for surgery or transcatheter repair.

  6. Jade Biosciences registers Phase 3 study of JADE101 in IgA nephropathy

    The study, titled the EVERGREEN STUDY, plans to enroll 480 participants and has a planned start date of December 2026. It will evaluate the safety and efficacy of JADE101 versus placebo in adults with immunoglobulin A nephropathy.

  7. Janssen registers Ramantamig and Daratumumab versus DVRd trial in newly diagnosed multiple myeloma

    The study, led by Janssen Research & Development, LLC, plans to enroll 1000 participants and is scheduled to start on December 14, 2026. It compares Ramantamig plus Daratumumab with the standard DVRd regimen followed by high-dose therapy, autologous stem cell transplant, and maintenance therapy.

  8. Jiangsu Simcere registers Phase II/III trial of SIM0811 in acute ischemic stroke

    Planned enrollment is 1092 participants and the study is expected to start on November 30, 2026, with primary completion projected for June 30, 2029. Researchers will compare different doses of SIM0811 to a placebo in patients treated within 4.5 to 24 hours after last known well.

  9. Alexion posts results of Phase 3 ARTEMIS ravulizumab trial

    The company posted results for its Phase 3 ARTEMIS study, which enrolled 555 participants and was terminated after primary completion on October 7, 2025. The trial assessed a single dose of ravulizumab IV versus placebo in adult participants with CKD undergoing non-emergent cardiac surgery with cardiopulmonary bypass.

  10. Boehringer Ingelheim posts results of 1-yr Tiotropium/Salmeterol study in COPD

    Results for the 220-participant, Phase 3, randomized, triple-masked study were posted on October 29, 2026. The study compared FDC tiotropium/salmeterol with single agents and assessed FEV1, dyspnoea, health status and exacerbations.

  11. Talazoparib plus enzalutamide versus placebo in metastatic APMR prostate cancer

    The authors reported that 805 patients were enrolled in the TALAPRO-2 phase 3 trial, with 402 assigned to talazoparib plus enzalutamide and 403 to placebo plus enzalutamide. Median follow-up for radiographic progression-free survival was 24·9 months for the talazoparib group and 24·6 months for the placebo group.

  12. Ray Therapeutics registers Phase 2/3 trial of RTx-015 in retinitis pigmentosa

    The study plans to enroll 60 participants and is expected to start in October 2026, with primary completion projected for October 2028. It aims to evaluate the effectiveness and safety of a single intravitreal injection of the investigational gene therapy RTx-015 in participants with retinitis pigmentosa.